AMA concerned about Walmart opioid prescription policy

The American Medical Association (AMA) recently sent a letter to Walmart Inc.’s chief medical and analytics officer to express its concerns about Walmart’s corporate prescription opioid “refusal to fill” policy.

AMA believes that, “Walmart’s corporate policy to limit opioid prescriptions to seven days or 50 morphine milligram equivalents (MME) has caused harm to patients with acute, palliative, cancer-related, chronic pain and other medical conditions requiring amounts or doses greater than your corporate policy.”

AMA is also suggesting that Walmart “provide [AMA] with the detailed data sources and analytical tools that are being used to create the algorithms and decision points behind [its] ‘refusal to fill’ policy.”

AMA Walmart letter